



# Financial Tear Sheet

## Corporate Profile

ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD's first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. Additional clinical trials of Iclusig in other cancers are ongoing. ARIAD is also studying AP26113, another molecularly targeted medicine, in certain forms of lung cancer.

## Primary IR Contact

Manmeet Soni  
Chief Financial Officer  
ARIAD Pharmaceuticals,  
Inc.

Phone: 617-503-7298


E-mail:  
[manmeet.soni@ariad.com](mailto:manmeet.soni@ariad.com)

## Stock Performance

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	\$23.99
<b>Change (%)</b>	0.00 (0.00%)
<b>Volume</b>	0
<b>52 Week Low</b>	\$4.67
<b>Market Cap</b>	\$4,658,878,679
<b>Rolling EPS</b>	-0.18
<b>PE Ratio</b>	0

**Shares Outstanding** 194,200,862

Data as of 02/15/17 4:15 p.m. ET



## Recent Headlines & Events

There are currently no events scheduled.

## Analyst Estimates / Ratings

**Mean Recommendation:3.0**



Sell

Strong Buy

Unable to fulfill request.

## SEC Filings

Filing Date	Form
04/07/17	SC 13G/A
02/27/17	CT ORDER
02/27/17	15-12B
02/21/17	SC 13D/A

## Corporate Governance

<a href="#">Harvey J. Berger, M.D.</a>	Chairman and Chief Executive Officer
<a href="#">David Berstein, Esq.</a>	Senior Vice President and Chief Intellectual Property Officer
<a href="#">Daniel M. Bollag, Ph.D.</a>	Senior Vice President of Regulatory Affairs and Quality
<a href="#">Joseph Bratica</a>	Vice President, Finance and Controller
<a href="#">Maria E. Cantor</a>	Senior Vice President, Corporate Affairs
<a href="#">Timothy P. Clackson, Ph.D.</a>	President of Research and Development and Chief Scientific Officer
<a href="#">David C. Dalgarno, Ph.D.</a>	Vice President, Research Technologies
<a href="#">Jonathan E. Dickinson</a>	Vice President, European Operations

and General Manager,  
ARIAD  
Pharmaceuticals  
(Europe), Sarl

[Pierre F. Dodion, M.D., M.B.A](#) Senior Vice President,  
Corporate  
Development and  
Operations

[Martin J. Duvall](#) Senior Vice President,  
Commercial  
Operations

[Edward M. Fitzgerald](#) Executive Vice  
President, Chief  
Financial Officer and  
Treasurer

[Frank G. Haluska, M.D., Ph.D.](#) Chief Medical Officer  
and Senior Vice  
President, Clinical  
R&D

[Shirish Hirani, Ph.D.](#) Vice President,  
Program and Alliance  
Management

[Stephen R. Jamieson](#) Vice President,  
Information  
Technology

[Raymond T. Keane, Esq.](#) Senior Vice President,  
General Counsel,  
Secretary and Chief  
Compliance Officer

[Ronald K. Knickerbocker, Ph.D.](#) Vice President,  
Biomedical Data  
Sciences and  
Information

[Jing L. Marantz, M.D., Ph.D.](#) Vice President,  
Medical Affairs

[Victor M. Rivera, Ph.D.](#) Vice President,  
Preclinical and  
Translational Research

[William C. Shakespeare, Ph.D.](#) Vice President, Drug  
Discovery

## Ownership Summary

	<b>Holders</b>	<b>Value (\$MM)</b>	<b>% O/S</b>	<b>Shares</b>
Institution	12	51.13	0.0	5,705,924
Mutual Fund	8	96.31	0.0	5,664,388
Insider *	0	.00	0.0	0

\*Insider values reflect direct beneficial ownership.

### Top Holders

	<b>Shares Held</b>	<b>% O/S</b>	<b>Share Change</b>	<b>Filing Date</b>
Berger (Harvey J)	4,371,103	0.0	0	05/20/16
LaMarche (Jay R)	549,526	0.0	-9,375	05/20/16
Fitzgerald (Edward M)	320,995	0.0	0	05/20/16
Wilson (Wayne)	116,125	0.0	-9,375	05/20/16
Cougar Capital LLC	115,900	0.0	5,000	12/31/16
Duvall (Martin J)	107,260	0.0	12,150	05/20/16
EverPoint Asset Management, LLC	45,000	0.0	45,000	12/31/16
DesRosier (Thomas J J.D.)	36,630	0.0	0	05/20/16
Waddell & Reed Investment Management Company	20,300	0.0	-257,700	08/31/16
Jackson Square Partners, LLC	8,885	0.0	8,885	12/31/16

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)